Pharmaceutical

5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends

Globaldata's analysis focuses on three key indicators, which include HTA outcomes in the 5EU and the entry of newly priced innovative drugs.

May 10, 2025 - 06:00
5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends
Globaldata's analysis focuses on three key indicators, which include HTA outcomes in the 5EU and the entry of newly priced innovative drugs.
Read the original article

Tags:

Previous Article

Unraveling the Link Between Fat, Ascites, and Anti-Tumor Immunity

Next Article

HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medic...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Researchers use AI to measure recovery from treatment-resistant depression

Researchers use AI to measure recovery from treatment-r...

Sep 20, 2023

How did hiring in the Chinese pharma industry perform in Q2 2023

How did hiring in the Chinese pharma industry perform i...

Jul 29, 2023

GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with anaemia

GSK’s Ojjaara receives FDA approval for treating myelof...

Sep 21, 2023